JP2005528414A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005528414A5 JP2005528414A5 JP2004500867A JP2004500867A JP2005528414A5 JP 2005528414 A5 JP2005528414 A5 JP 2005528414A5 JP 2004500867 A JP2004500867 A JP 2004500867A JP 2004500867 A JP2004500867 A JP 2004500867A JP 2005528414 A5 JP2005528414 A5 JP 2005528414A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- treatment
- progresses
- radiation therapy
- radiotherapy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 238000001959 radiotherapy Methods 0.000 claims 25
- 238000000034 method Methods 0.000 claims 20
- 206010028980 Neoplasm Diseases 0.000 claims 15
- 201000011510 cancer Diseases 0.000 claims 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 13
- 230000002250 progressing effect Effects 0.000 claims 10
- 201000001342 Fallopian tube cancer Diseases 0.000 claims 9
- 208000013452 Fallopian tube neoplasm Diseases 0.000 claims 9
- 150000003058 platinum compounds Chemical class 0.000 claims 9
- 125000000217 alkyl group Chemical group 0.000 claims 8
- 229910052739 hydrogen Inorganic materials 0.000 claims 8
- 239000001257 hydrogen Substances 0.000 claims 8
- 150000003883 epothilone derivatives Chemical class 0.000 claims 7
- 201000007270 liver cancer Diseases 0.000 claims 7
- 208000014018 liver neoplasm Diseases 0.000 claims 7
- 206010009944 Colon cancer Diseases 0.000 claims 6
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 6
- 102000004127 Cytokines Human genes 0.000 claims 5
- 108090000695 Cytokines Proteins 0.000 claims 5
- 206010033128 Ovarian cancer Diseases 0.000 claims 5
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 5
- 208000026149 Primary peritoneal carcinoma Diseases 0.000 claims 5
- 206010060862 Prostate cancer Diseases 0.000 claims 5
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 5
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 5
- 229940045985 antineoplastic platinum compound Drugs 0.000 claims 5
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims 5
- 229960004768 irinotecan Drugs 0.000 claims 5
- 201000001441 melanoma Diseases 0.000 claims 5
- 238000013059 nephrectomy Methods 0.000 claims 5
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims 5
- 229960001756 oxaliplatin Drugs 0.000 claims 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 4
- 206010027476 Metastases Diseases 0.000 claims 4
- 229940123237 Taxane Drugs 0.000 claims 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 4
- 238000011474 orchiectomy Methods 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 241001465754 Metazoa Species 0.000 claims 2
- 208000004019 papillary adenocarcinoma Diseases 0.000 claims 2
- 229940125714 antidiarrheal agent Drugs 0.000 claims 1
- 239000003793 antidiarrheal agent Substances 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229930013356 epothilone Natural products 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 230000005855 radiation Effects 0.000 claims 1
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 claims 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- -1 fatty acid esters Chemical class 0.000 description 6
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 125000005456 glyceride group Chemical group 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- WQEPLUUGTLDZJY-UHFFFAOYSA-N pentadecanoic acid Chemical compound CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 3
- 229920001223 polyethylene glycol Chemical class 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- OIQOAYVCKAHSEJ-UHFFFAOYSA-N 2-[2,3-bis(2-hydroxyethoxy)propoxy]ethanol;hexadecanoic acid;octadecanoic acid Chemical compound OCCOCC(OCCO)COCCO.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O OIQOAYVCKAHSEJ-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Chemical class 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 238000006136 alcoholysis reaction Methods 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- UKMSUNONTOPOIO-UHFFFAOYSA-N docosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCC(O)=O UKMSUNONTOPOIO-UHFFFAOYSA-N 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- ZQPPMHVWECSIRJ-MDZDMXLPSA-N elaidic acid Chemical compound CCCCCCCC\C=C\CCCCCCCC(O)=O ZQPPMHVWECSIRJ-MDZDMXLPSA-N 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 150000002334 glycols Chemical class 0.000 description 2
- 239000007902 hard capsule Substances 0.000 description 2
- KEMQGTRYUADPNZ-UHFFFAOYSA-N heptadecanoic acid Chemical compound CCCCCCCCCCCCCCCCC(O)=O KEMQGTRYUADPNZ-UHFFFAOYSA-N 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- VKOBVWXKNCXXDE-UHFFFAOYSA-N icosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCC(O)=O VKOBVWXKNCXXDE-UHFFFAOYSA-N 0.000 description 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- SZHOJFHSIKHZHA-UHFFFAOYSA-N tridecanoic acid Chemical compound CCCCCCCCCCCCC(O)=O SZHOJFHSIKHZHA-UHFFFAOYSA-N 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- UZFMOKQJFYMBGY-UHFFFAOYSA-N 4-hydroxy-TEMPO Chemical compound CC1(C)CC(O)CC(C)(C)N1[O] UZFMOKQJFYMBGY-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 235000019489 Almond oil Nutrition 0.000 description 1
- 235000021357 Behenic acid Nutrition 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 239000005662 Paraffin oil Substances 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 229940116226 behenic acid Drugs 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 239000010685 fatty oil Substances 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 150000004668 long chain fatty acids Chemical class 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 235000003441 saturated fatty acids Nutrition 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37706302P | 2002-05-01 | 2002-05-01 | |
| PCT/EP2003/004581 WO2003092683A1 (en) | 2002-05-01 | 2003-04-30 | Epothilone derivative for the treatment of hepatoma and other cancer diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005528414A JP2005528414A (ja) | 2005-09-22 |
| JP2005528414A5 true JP2005528414A5 (enExample) | 2006-06-08 |
Family
ID=29401440
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004500867A Pending JP2005528414A (ja) | 2002-05-01 | 2003-04-30 | 肝臓癌および他の癌疾患の処置用エポチロン誘導体 |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US20050282873A1 (enExample) |
| EP (1) | EP1503756B1 (enExample) |
| JP (1) | JP2005528414A (enExample) |
| KR (1) | KR20040106422A (enExample) |
| CN (1) | CN1649585A (enExample) |
| AT (1) | ATE439130T1 (enExample) |
| AU (1) | AU2003227702B2 (enExample) |
| BR (1) | BR0309711A (enExample) |
| CA (1) | CA2483826C (enExample) |
| CY (1) | CY1109607T1 (enExample) |
| DE (1) | DE60328772D1 (enExample) |
| DK (1) | DK1503756T3 (enExample) |
| ES (1) | ES2330324T3 (enExample) |
| IL (1) | IL164783A (enExample) |
| MX (1) | MXPA04010853A (enExample) |
| NO (1) | NO20045249L (enExample) |
| NZ (1) | NZ536178A (enExample) |
| PL (1) | PL211114B1 (enExample) |
| PT (1) | PT1503756E (enExample) |
| RU (1) | RU2358730C2 (enExample) |
| SI (1) | SI1503756T1 (enExample) |
| WO (1) | WO2003092683A1 (enExample) |
| ZA (1) | ZA200408492B (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1649585A (zh) * | 2002-05-01 | 2005-08-03 | 诺瓦提斯公司 | 用于治疗肝脏肿瘤和其它癌症疾病的埃坡霉素衍生物 |
| CN1870995A (zh) * | 2003-09-02 | 2006-11-29 | 诺瓦提斯公司 | 使用埃坡霉素的癌症治疗 |
| US8394365B2 (en) | 2003-09-17 | 2013-03-12 | Nektar Therapeutics | Multi-arm polymer prodrugs |
| EP1640004A1 (en) * | 2004-09-24 | 2006-03-29 | Schering Aktiengesellschaft | Use of epothilones in the treatment of bone metastases and bone tumors or cancers |
| WO2006055742A1 (en) * | 2004-11-18 | 2006-05-26 | Bristol-Myers Squibb Company | Enteric coated bead comprising epothilone or epothilone analog, and preparation and administration thereof |
| US20060121511A1 (en) | 2004-11-30 | 2006-06-08 | Hyerim Lee | Biomarkers and methods for determining sensitivity to microtubule-stabilizing agents |
| EP2634252B1 (en) | 2005-02-11 | 2018-12-19 | University of Southern California | Method of expressing proteins with disulfide bridges |
| US8008256B2 (en) | 2006-05-01 | 2011-08-30 | University Of Southern California | Combination therapy for treatment of cancer |
| MX2008004267A (es) * | 2008-03-28 | 2009-09-28 | Posi Visionary Solutions Llp | Metoclopramida de liberacion prolongada de 12 horas. |
| MX2008004268A (es) * | 2008-03-28 | 2009-09-28 | Posi Visionary Solutions Llp | Metoclopramida de liberacion prolongada de 24 horas. |
| US8802394B2 (en) | 2008-11-13 | 2014-08-12 | Radu O. Minea | Method of expressing proteins with disulfide bridges with enhanced yields and activity |
| CN101747326B (zh) * | 2010-01-12 | 2012-07-25 | 山东大学 | 18元大环内酯类埃博霉素化合物及其应用 |
| CA2927832C (en) | 2010-05-18 | 2021-03-23 | Cerulean Pharma Inc. | Cyclodextrin-containing polymer-therapeutic agent conjugates and their use |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6204388B1 (en) * | 1996-12-03 | 2001-03-20 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
| US6660758B1 (en) * | 1996-12-13 | 2003-12-09 | The Scripps Research Institute | Epothilone analogs |
| US6194181B1 (en) * | 1998-02-19 | 2001-02-27 | Novartis Ag | Fermentative preparation process for and crystal forms of cytostatics |
| US6302838B1 (en) * | 1998-02-25 | 2001-10-16 | Novartis Ag | Cancer treatment with epothilones |
| EE04852B1 (et) * | 1999-02-22 | 2007-06-15 | Gesellschaft Fuer Biotechnologische Forschung Mbh | C-21 modifitseeritud epotioloonid, nende valmistamise meetod ning kasutamine ja ravimkoostise kasutamine vähkkasvajate või teiste proliferatiivsete haiguste ravimisel |
| GB9918429D0 (en) * | 1999-08-04 | 1999-10-06 | Novartis Ag | Organic compounds |
| CN1649585A (zh) * | 2002-05-01 | 2005-08-03 | 诺瓦提斯公司 | 用于治疗肝脏肿瘤和其它癌症疾病的埃坡霉素衍生物 |
-
2003
- 2003-04-30 CN CNA038097702A patent/CN1649585A/zh active Pending
- 2003-04-30 BR BR0309711-0A patent/BR0309711A/pt active Search and Examination
- 2003-04-30 SI SI200331688T patent/SI1503756T1/sl unknown
- 2003-04-30 PL PL371727A patent/PL211114B1/pl not_active IP Right Cessation
- 2003-04-30 EP EP03725129A patent/EP1503756B1/en not_active Expired - Lifetime
- 2003-04-30 US US10/512,504 patent/US20050282873A1/en not_active Abandoned
- 2003-04-30 AT AT03725129T patent/ATE439130T1/de active
- 2003-04-30 KR KR10-2004-7017468A patent/KR20040106422A/ko not_active Ceased
- 2003-04-30 DE DE60328772T patent/DE60328772D1/de not_active Expired - Lifetime
- 2003-04-30 PT PT03725129T patent/PT1503756E/pt unknown
- 2003-04-30 JP JP2004500867A patent/JP2005528414A/ja active Pending
- 2003-04-30 RU RU2004135307/15A patent/RU2358730C2/ru not_active IP Right Cessation
- 2003-04-30 AU AU2003227702A patent/AU2003227702B2/en not_active Ceased
- 2003-04-30 WO PCT/EP2003/004581 patent/WO2003092683A1/en not_active Ceased
- 2003-04-30 DK DK03725129T patent/DK1503756T3/da active
- 2003-04-30 MX MXPA04010853A patent/MXPA04010853A/es active IP Right Grant
- 2003-04-30 CA CA2483826A patent/CA2483826C/en not_active Expired - Fee Related
- 2003-04-30 ES ES03725129T patent/ES2330324T3/es not_active Expired - Lifetime
- 2003-04-30 NZ NZ536178A patent/NZ536178A/en not_active IP Right Cessation
-
2004
- 2004-10-20 ZA ZA200408492A patent/ZA200408492B/en unknown
- 2004-10-21 IL IL164783A patent/IL164783A/en not_active IP Right Cessation
- 2004-11-30 NO NO20045249A patent/NO20045249L/no not_active Application Discontinuation
-
2008
- 2008-03-11 US US12/046,017 patent/US20080161369A1/en not_active Abandoned
-
2009
- 2009-11-11 CY CY20091101180T patent/CY1109607T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023036950A (ja) | 癌治療のための組み合わせ療法 | |
| JP2006501134A (ja) | 高い生物学的利用能を有する、経口活性タキサン誘導体の医薬組成物 | |
| US20150094292A1 (en) | Topical compositions containing nitro fatty acids | |
| RU2002122744A (ru) | Новая самоэмульгирующаяся система доставки лекарств | |
| RU2002119568A (ru) | Композиции для доставки антагониста кортизола | |
| JP2003525894A5 (enExample) | ||
| JP2011503063A5 (enExample) | ||
| US20230321022A1 (en) | Reversibly protected thiolated electrophilic fatty acids as prodrugs | |
| JP2003525893A5 (enExample) | ||
| JP2012162577A (ja) | がん治療のための細胞増殖抑制剤及び電子受容体を含有する医薬製剤 | |
| JP2023036663A (ja) | 重水素化ドンペリドンを含む製剤 | |
| KR20140016926A (ko) | 활성제로서 페닐아미노피리미딘 유도체를 포함하는 제제 | |
| RU2358730C2 (ru) | Производное эпотилона для лечения гепатомы и других раковых заболеваний | |
| RU2651471C2 (ru) | Фармацевтическая композиция, содержащая 11-дезокси-простагландиновое соединение, и способ стабилизации этого соединения | |
| JP2013504590A (ja) | 非放射性リン脂質化合物、組成物、及び使用方法 | |
| JP5734331B2 (ja) | 二環式化合物を含む医薬組成物およびその二環式化合物の安定化方法 | |
| EP3439644A1 (en) | Isoflavonoid composition with improved pharmacokinetics | |
| JPH07503728A (ja) | テトラアリールエチレン類による多剤耐性の逆転 | |
| AU2018315094A1 (en) | Methods and compositions for treatment of inflammatory bowel disease | |
| EP3522885A1 (en) | Novel reversible nitroxide derivatives of nitroalkenes that mediate nitrosating and alkylating reactions | |
| CN110402142A (zh) | 含局麻药的酸性乳液组合物 | |
| KR20220161356A (ko) | 자발적 수용이 개선된 조성물 | |
| CN101505727A (zh) | 用于口服给药的药物组合物 | |
| JP5223307B2 (ja) | 坐剤 | |
| JP2005132766A (ja) | 光動力学的癌治療薬 |